Biosketch

A native of Minnesota, Dr. David Stroncek completed his undergraduate and medical school degrees, an internal medicine residency, and a hematology/oncology fellowship at the University of Minnesota. He then joined the faculty of the University of Minnesota Medical School, Laboratory Medicine and Pathology Department and later became medical director of the blood blank.

He helped establish the National Marrow Donor Program (NMDP) and was the organization's first medical director. During his four years as medical director of the NMDP, the program coordinated their first unrelated donor transplant and subsequently increased the number of marrow donations by unrelated individuals. He has served on several NMDP committees as president of the council of the NMDP and as a member of the NMDP board of directors.

Dr. Stroncek came to the NIH Clinical Center Department of Transfusion Medicine (DTM) in 1996 as chief of the Laboratory Service Section. In this role, he directed the HLA and Transfusion Services Laboratories.

During his tenure, the HLA laboratory moved from a serological laboratory to a molecular testing laboratory that provided sequence-specific probe, high resolution sequence-specific primer, and sequence-based HLA genotyping. Under Dr. Stroncek's direction, the Transfusion Service Laboratory began genotyping RBC antigens and discovered that the low pH and high osmolarity of citrate anticoagulant in blood components caused RBCs from donors with sickle cell trait to occlude leukocyte reduction filters.

Dr. Stroncek became chief of the Cell Processing Section in 2007. Under his direction the Section has collaborated with Institute Investigators to develop and implement methods to produce clinical Natural Killer cell, Th2 Rapamycin cell and dendritic cell products. The Section has also developed a new program to produce Bone Marrow Stromal Cells and is working with the Surgery Branch NCI to improve the growth and expansion of TIL using gas-permeable flasks. He is also using gene and micro RNA expression profiling to improve potency and stability testing of cellular therapies.

He has published more than 230 articles in scientific journals and has written several book chapters. He has served on the editorial boards of several scientific journals.

Selected Publications

JOURNAL REVIEWS

Castiello L, Sabatino M, Jin P, Clayberger C, Marincola FM, Krensky AM, Stroncek DF. Monocyte-derived DC maturation strategies and related pathways: a transcriptional view. Cancer Immunol Immunother. 2011 Apr;60(4):457-66

Stroncek DF. Neutrophil-specific antigen HNA-2a, NB1 glycoprotein, and CD177. Curr Opin Hematol. 2007 Nov;14(6):688-93.

Stroncek DF, Rebulla P. Platelet transfusions. Lancet. 2007 Aug 4;370(9585):427-38.

Stroncek DF, Jin P, Wang E, Jett B. Potency analysis of cellular therapies: the emerging role of molecular assays. J Transl Med. 2007 May 30;5:24.

Stroncek D. Neutrophil alloantigens. Transfus Med Rev. 2002 Jan;16(1):67-75.

JOURNAL ARTICLES

Jin P, Han TH, Ren J, Saunders S, Wang E, Marincola FM, Stroncek DF. Molecular signatures of maturing dendritic cells: implications for testing the quality of dendritic cell therapies. J Transl Med. 2010 Jan 15;8:4.

Donahue RE, Jin P, Bonifacino AC, Metzger ME, Ren J, Wang E, Stroncek DF. Plerixafor (AMD3100) and granulocyte colony-stimulating factor (G-CSF) mobilize different CD34+ cell populations based on global gene and microRNA expression signatures. Blood. 2009 Sep 17;114(12):2530-41..

Shin JW, Jin P, Fan Y, Slezak S, David-Ocampo V, Khuu HM, Read EJ, Wang E, Marincola FM, Stroncek DF. Evaluation of gene expression profiles of immature dendritic cells prepared from peripheral blood mononuclear cells. Transfusion. 2008 Apr;48(4):647-57.

Lim JB, Provenzano M, Kwon OH, Bettinotti M, Caruccio L, Nagorsen D, Stroncek D. Identification of HLA-A33-restricted CMV pp65 epitopes as common targets for CD8(+) CMV-specific cytotoxic T lymphocytes. Exp Hematol. 2006 Mar;34(3):296-307.

Stroncek DF, Rainer T, Sharon V, Byrne KM, Noguchi CT, Klein HG, Schechter AN, Leitman SF. Sickle Hb polymerization in RBC components from donors with sickle cell trait prevents effective WBC reduction by filtration. Transfusion. 2002 Nov;42(11):1466-72.

Stroncek DF, Clay ME, Petzoldt ML, Smith J, Jaszcz W, Oldham FB, McCullough J. Treatment of normal individuals with granulocyte-colony-stimulating factor: donor experiences and the effects on peripheral blood CD34+ cell counts and on the collection of peripheral blood stem cells. Transfusion. 1996 Jul;36(7):601-10.

Stroncek DF, Holland PV, Bartch G, Bixby T, Simmons RG, Antin JH, Anderson KC, Ash RC, Bolwell BJ, Hansen JA, et al. Experiences of the first 493 unrelated marrow donors in the National Marrow Donor Program. Blood. 1993 Apr 1;81(7):1940-6.

Stroncek DF, Vercellotti GM, Hammerschmidt DE, Christie DJ, Shankar RA, Jacob HS. Characterization of multiple quinine-dependent antibodies in a patient with episodic hemolytic uremic syndrome and immune agranulocytosis. Blood. 1992 Jul 1;80(1):241-8.

Stroncek DF, Skubitz KM, Plachta LB, Shankar RA, Clay ME, Herman J, Fleit HB, McCullough J. Alloimmune neonatal neutropenia due to an antibody to the neutrophil Fc-gamma receptor III with maternal deficiency of CD16 antigen. Blood. 1991 Apr 1;77(7):1572-80.

Stroncek DF, Skubitz KM, McCullough J. Biochemical characterization of the neutrophil-specific antigen NB1.Blood. 1990 Feb 1;75(3):744-55.